Overview
Enveda is an AI biotech company founded in 2019 by Viswa Colluru (ex-Recursion Pharmaceuticals) in Boulder, Colorado. The company discovers drugs from plants and microbes using its PRISM AI platform, with multiple candidates in human clinical trials.
Recent Developments
- 2026-09-23: Raised 845M; $2B valuation (2× YoY per TechCrunch) (2026-09-23-enveda-311m-ai-drug-funding, 2026-09-23-enveda-biospace-series-e-official)
- Three clinical-stage candidates: atopic dermatitis (ENV-294), post-GLP-1 weight maintenance (ENV-308), inflammatory bowel disease
- Two positive early clinical readouts in 2026 (atopic dermatitis, metabolic)
- George Petrocheilos (Catalio) joined board
- New investors: Durable Capital, ICONIQ, Lightspeed, Surveyor Capital, T. Rowe Price, Digitalis Ventures
$2B valuation reported by TechCrunch only; official press release did not disclose valuation.